The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER

Thavichachart, Nuntika; Kongsakon, Ronnachai; Lo, William Tak Lam; Lim, Liangzhong; Singh, Sandhya; Sobrevega, E.; Banaag, Cecilia B.; Bautista, J.; Evangelista, Maria Laura; Dimatalac, B.; Choi, A Ra; Nerapusee, Osot

doi:10.1111/j.1742-1241.2012.03016.x

Cited by 4 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No unexpected tolerability finding was observed. The overall discontinuation rate of this study is consistent with other recent published articles 17–19. The percentage of patients discontinuing due to adverse events was relatively low (7.5%).…”

Section: Discussionsupporting

confidence: 91%

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

Charnsil¹,

Vongpanich²

2013

NDT

View full text Add to dashboard Cite

BackgroundPrevious studies with extended-release (ER) paliperidone have reported an effective outcome in terms of personal and social functioning improvement and also reported schizophrenia symptom improvement. The main objectives of this study were to further investigate improvements in symptom control and social functioning of paliperidone ER and acknowledge the safety profile of paliperidone ER in Thai patients with schizophrenia.Patients and methodsPatients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders criteria were allowed flexible 3–12 mg/day dosing during the 10-week study duration. Patients were interviewed and assessed in social functioning using the Personal and Social Performance (PSP) scale. Patients were also rated on overall severity of illness using the Clinical and Global Impressions – Severity (CGI-S) scale.ResultsIn total, 40 patients were enrolled, 80% of enrolled patients (n = 32) completed the 10-week study period. Thirty-eight eligible patients were included in the intention-to-treat analysis set (male 39.5%, female 60.5%). One patient was lost to follow-up without postbaseline-efficacy measurements. Another patient was terminated early due to a change in diagnosis during the trial. Statistically significant improvements from baseline in PSP total score were observed at all time points. Clinically relevant improvement in PSP (increase of at least one 10-point category) was observed in 47.40% of patients at end point. Improvement in CGI-S was observed at end point (P < 0.001). The mean reduction ± standard deviation at end point in CGI-S was 0.8 ± 1.04 (95% confidence interval 0.48–1.16). The most commonly reported adverse events (≥5% of patients) were daytime drowsiness (15%) and headache (15%). Three subjects (7.5%) discontinued due to adverse events.ConclusionThis study suggests that paliperidone ER is well tolerated in Thai patients with schizophrenia. Paliperidone ER showed improvement in schizophrenic symptom control and social functioning.

show abstract

Section: Discussionsupporting

confidence: 91%

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

Charnsil¹,

Vongpanich²

2013

NDT

View full text Add to dashboard Cite

show abstract

“…This study is a part of the Paliperidone ER Functionality, Efficacy and Tolerability (PERFEcT) Study, a 6-month, open-label, multicenter, multi-country, prospective trial to explore the safety, efficacy, and functionality of paliperidone extended-release tablets. 17 The current study included only the baseline data obtained from Thai participants. The study was approved by the Ethics Committee or the Institution Review Board of each participating site.…”

Section: Methodsmentioning

confidence: 99%

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Suttajit¹,

Arunpongpaisal²,

Srisurapanont³

et al. 2015

NDT

View full text Add to dashboard Cite

This study aimed to examine symptoms/demographic characteristics as predictors for psychosocial functioning among individuals with schizophrenia. The Personal and Social Performance (PSP) scale was used to assess psychosocial functioning. Other measures of interest included were the Clinical Global Impression, Severity scale, and the Marder’s five-factor model of the Positive and Negative Syndrome Scale. This study included 199 participants with non-acute stage schizophrenia. Spearman correlation coefficients and stepwise multiple linear regression analyses were applied to determine the correlates and predictors of PSP domain/total scores. Younger age, earlier age of schizophrenia onset, severe illness, positive symptoms, negative symptoms, disorganized thought, hostility/excitement, and anxiety/depression were found to significantly correlate with poor functioning. Severe illness and negative symptoms are the main predictors of greater impairment of socially useful activities, personal and social relationships, and self-care. Further prospective studies in other settings, which would include an increased number of variables such as neurocognitive function and social support, are warranted.

show abstract

“…This finding is consistent with previous results that showed that schizophrenia patients with higher PANSS scores have a greater response to antipsychotics than those with lower PANSS scores. 11 …”

Section: Discussionmentioning

confidence: 99%

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia

Kongsakon

Thavichachart

Chung³

et al. 2017

PRBM

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of 6 months of treatment with paliperidone extended-release (ER) tablets on the sleep profile of patients with schizophrenia.MethodsA total of 984 patients meeting the The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia who switched their antipsychotic to paliperidone ER were recruited from 61 sites in five countries in Southeast Asia. We recorded patient demographics and assessed sleep quality and daytime drowsiness using visual analog scales.ResultsApproximately 70% of patients completed the 6-month study. After the use of paliperidone ER, patients reported significantly better sleep quality (76.44 vs 65.48; p<0.001) and less daytime drowsiness compared with their baseline value (23.18 vs 34.22; p<0.001). Factors predicting sleep profile improvement were completion of the study and higher baseline Positive and Negative Syndrome Scale scores.ConclusionPaliperidone ER can help schizophrenia patients to improve sleep quality and reduce daytime drowsiness; this was seen especially in the patients who completed the 6-month treatment period and had higher baseline Positive and Negative Syndrome Scale scores.

show abstract

The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER

Cited by 4 publications

References 20 publications

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia

Contact Info

Product

Resources

About